{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transthyretin+Amyloid+Cardiopathy&page=2",
    "query": {
      "condition": "Transthyretin Amyloid Cardiopathy",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transthyretin+Amyloid+Cardiopathy&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T21:33:38.922Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06679946",
      "title": "A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Transthyretin Amyloidosis (ATTR) With Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "Vutrisiran",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 700,
      "start_date": "2024-12-03",
      "completion_date": "2028-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-20",
      "last_synced_at": "2026-07-23T21:33:38.922Z",
      "location_count": 24,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06679946"
    },
    {
      "nct_id": "NCT02292186",
      "title": "A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "TTR-mediated Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Revusiran (ALN-TTRSC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 25,
      "start_date": "2014-10",
      "completion_date": "2017-02-22",
      "has_results": true,
      "last_update_posted_date": "2020-07-09",
      "last_synced_at": "2026-07-23T21:33:38.922Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York • Cleveland, Ohio",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02292186"
    },
    {
      "nct_id": "NCT03812172",
      "title": "Screening for Cardiac Amyloidosis With Nuclear Imaging for Minority Populations",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Amyloid Cardiomyopathy, Transthyretin-Related"
      ],
      "interventions": [
        {
          "name": "99mTc-PYP or 99m Tc-HDP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mathew S. Maurer, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 646,
      "start_date": "2019-05-15",
      "completion_date": "2024-12-13",
      "has_results": true,
      "last_update_posted_date": "2025-11-19",
      "last_synced_at": "2026-07-23T21:33:38.922Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03812172"
    },
    {
      "nct_id": "NCT05505838",
      "title": "Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Transthyretin-mediated Amyloidosis With Cardiomyopathy",
        "ATTR Amyloidosis With Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "Patisiran",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2024-02-16",
      "last_synced_at": "2026-07-23T21:33:38.922Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • San Diego, California + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05505838"
    },
    {
      "nct_id": "NCT03414632",
      "title": "Transthyretin Cardiac Amyloidosis in HFpEF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Heart Failure With Preserved Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "99mTc-PYP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 287,
      "start_date": "2017-12-01",
      "completion_date": "2020-03-31",
      "has_results": false,
      "last_update_posted_date": "2021-03-19",
      "last_synced_at": "2026-07-23T21:33:38.922Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03414632"
    },
    {
      "nct_id": "NCT02319005",
      "title": "ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)",
        "Amyloidosis, Hereditary",
        "Amyloid Neuropathies, Familial",
        "Amyloid Neuropathies",
        "Amyloidosis, Hereditary, Transthyretin-Related",
        "Familial Transthyretin Cardiac Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Revusiran (ALN-TTRSC)",
          "type": "DRUG"
        },
        {
          "name": "Sterile Normal Saline (0.9% NaCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 206,
      "start_date": "2014-12",
      "completion_date": "2017-03-30",
      "has_results": true,
      "last_update_posted_date": "2018-07-18",
      "last_synced_at": "2026-07-23T21:33:38.922Z",
      "location_count": 41,
      "location_summary": "Bakersfield, California • Beverly Hills, California • La Mesa, California + 30 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02319005"
    },
    {
      "nct_id": "NCT00694161",
      "title": "The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "Fx-1006A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2008-08",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2013-01-11",
      "last_synced_at": "2026-07-23T21:33:38.922Z",
      "location_count": 6,
      "location_summary": "Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 3 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00694161"
    },
    {
      "nct_id": "NCT03860935",
      "title": "Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Amyloidosis",
        "Amyloid Cardiomyopathy",
        "Transthyretin Amyloidosis",
        "Cardiomyopathies",
        "Heart Diseases"
      ],
      "interventions": [
        {
          "name": "acoramidis",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eidos Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 632,
      "start_date": "2019-03-19",
      "completion_date": "2023-05-11",
      "has_results": true,
      "last_update_posted_date": "2024-06-27",
      "last_synced_at": "2026-07-23T21:33:38.922Z",
      "location_count": 40,
      "location_summary": "Los Angeles, California • Santa Monica, California • Aurora, Colorado + 32 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03860935"
    },
    {
      "nct_id": "NCT02252653",
      "title": "DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Familial Amyloidotic Cardiomyopathy (FAC)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1010,
      "start_date": "2014-06",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2016-07-20",
      "last_synced_at": "2026-07-23T21:33:38.922Z",
      "location_count": 43,
      "location_summary": "Little Rock, Arkansas • Bakersfield, California • La Mesa, California + 32 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02252653"
    },
    {
      "nct_id": "NCT05374564",
      "title": "Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cardiomyopathies, Primary"
      ],
      "interventions": [
        {
          "name": "(18F)Flutemetamol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2022-08-16",
      "completion_date": "2024-11-14",
      "has_results": false,
      "last_update_posted_date": "2025-08-03",
      "last_synced_at": "2026-07-23T21:33:38.922Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05374564"
    }
  ]
}